Varian Medical Systems — Q2 2019 Earnings Presentation
33 slides from Varian Medical Systems's earnings presentation, Apr 24, 2019

Slide 1: Second Quarter Fiscal Year 2019
J. Michael Bruff Senior Vice President, Investor Relations investors@varian.com April 24, 2019 Second Quarter Fiscal Year 2019

Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199

Slide 3: Q2 FY 2019 earnings Agenda
VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 1. Second Quarter Results 2. Total Company Performance 3. Segment Performance 4. FY 2019 Guidance 5. Appendix Q2 FY 2019 earnings Agenda

Slide 4: Q2 FY 2019 key financial metrics
Q2 FY 2019 key financial metrics $M Q2 Y/Y Oncology Orders $766 15% Revenues $779 7% Oncology $747 7% Proton Solutions $33 2% GAAP Operating Earnings $110 1% % of Revenues 14.1% (90 bps) Non - GAAP Operating Earnings $119 (6%) % of Revenues 15.3% (220 bps) GAAP EPS $0.96 22% Non - GAAP EPS $1.05 (9%

Slide 5: Long-term growth and value creation strategy
Long - term growth and value creation strategy Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology S

Slide 6: How we plan to achieve our strategy
How we plan to achieve our strategy 6 Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Market Growth Priorities High Quality Care Through Innovation Build Software Services & Big Data Expertise Operational Efficiency Optimize Cash Conversion & Capital Structure S

Slide 7: Executing on long-term growth strategy
Executing on long - term growth strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Market 7 KEY METRICS • Global market leader with >50% share in radiation therapy; growing share in a +10% growth market 1 • +15% Oncology orders growth in the quarter; TTM g

Slide 8: Key wins
VARIAN CONFIDENTIAL – INTERNAL USE ONLY Key wins Americas EMEA APAC Alliance Oncology - Huntsville 3 TrueBeams, 3 Halcyons, and 1 Edge system with Enterprise Software Solution HCA 4 TrueBeams and 1 Halcyon system ABC Hospital TrueBeam package Brazil Replacement of cobalt system with Halcyon Scripps

Slide 9: Varian linac net installed base
Varian linac net installed base Installed base growth Varian strengthened its global leadership in radiation therapy • Net installed base grew +4% or 338 units, driving future recurring software and services revenues • All three geographies grew respective installed base in the second quarter Q2 FY1

Slide 10: Total Company Performance
Total Company Performance varian

Slide 11: Total company results (GAAP)
Total company results (GAAP) Key P&L financial metrics 11 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders, all growth rates are in dollars and year on year, and basis poi nts (bps) are rounded to the nearest tens. (1) TTM EPS is defined as the sum of last four quarters’ reported EPS

Slide 12: Total company results (non-GAAP)
Total company results (non - GAAP) Key P&L financial metrics 12 • Gross Orders driven by strong Oncology orders: +15% in the quarter and +13% over the trailing twelve months • Revenues growth driven by integrated platform of best - in - class hardware, software, and services • Gross Margin rate down

Slide 13: Total company results: key balance sheet and cash flow metrics
$- $100 $200 $300 Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 - 100% Y/Y Cash Flow from Operations ($M) -$50 $0 $50 $100 $150 $200 Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Total Debt ($M) Total company results Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) $400 $500 $600 $700 $800 Q

Slide 14: Capital allocation priorities
• Used $51M to repurchase 420K shares in Q2 • As of the end of the quarter, 2.9M shares remaining under our existing repurchase authorization Organic R&D and Capital Investments • Investments in adaptive radiotherapy, preclinical research with the FlashFoward Consortium, and other programs • Softwar

Slide 15: Segment Performance
Segment Performance varian

Slide 16: Oncology Systems segment (GAAP)
Oncology Systems segment (GAAP) Key financial metrics 16 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year. (1) Operating earnings includes an allocation of corporate costs based on relative revenues between the operating segments. T

Slide 17: Oncology Systems gross orders by geography
17 Oncology Systems gross orders by geography AMERICAS 7% Q2 Y/Y 1 (+8% c c) 8% TTM Y/Y 1 (+8% cc) APAC 35% Q2 Y/Y (+38% cc ) 20% TTM Y/Y (+21% cc ) EMEA 17% Q2 Y/Y (+25% cc ) 18% TTM Y/Y (+19% cc ) (1) In North America, Q2 orders growth of +12% and TTM orders growth of +9%

Slide 18: Proton Solutions segment (GAAP)
Proton Solutions segment (GAAP) Key financial metrics 18 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year. NM: Not meaningful. (1) Operating earnings includes an allocation of corporate costs based on relative revenues between the o

Slide 19: ProBeam proton therapy system sites
ProBeam proton therapy system sites Operational Centers Centers Under Development Total Rooms ProBeam Sites Operational R ooms 1 Operational Sites 70 30 10 23 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 19

Slide 20: FY 2019 Guidance
FY 2019 Guidance varian

Slide 21: Updated guidance for fiscal year 2019
Varian consolidated Updated guidance for fiscal year 2019 21 • Guidance considers projected market growth and continued momentum of Varian’s portfolio • Updated guidance considers the following impacts to operating earnings: $5 million increase from raise in revenue guidance $5 million benefit f

Slide 22: In summary, we are...
FOR INVESTOR USE ONLY In summary, we are… …Driving toward our vision of a world without fear of cancer Delivering on our long - term growth and value creation strategy Growing our net installed base Extending our global footprint and market - leading, best - in - class product portfolio Becoming a g

Slide 23: Appendix
Appendix

Slide 24: Non-GAAP disclosure
Non - GAAP disclosure 24 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

Slide 25: GAAP to non-GAAP reconciliation
GAAP to non - GAAP reconciliation 25 (1) Includes $1.5 million, $1.9 million, $1.9 million, $1.9 million and $2.9 million respectively, in cost of revenues for the pe rio ds presented. (2) Primarily includes a $22.0 million gain on the sale of our investment in Augmenix in the first quarter of fisca

Slide 26: Total revenues by sales classification
Total revenues by sales classification 26 $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $393.8 $365.0 $445.5 $400.2 $430.5 Y/Y 8% 14% 11% 9% 9% Service revenues $336.1 $344.1 $356.1 $340.8 $348.9 Y/Y 13% 10% 11% 9% 4% Total revenues $729.9 $709.1 $801.6 $741.0 $779.4 Y/Y 10% 12% 11% 9%

Slide 27: Total revenues by product type
Total revenues by product type 27 CC – Constant currency (1) Includes software support agreements that are recorded in revenues from service, and software licenses that are recorded in r eve nues from product, in the Condensed Consolidated Statements of Earnings. $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2

Slide 28: Total revenues by region
Total revenues by region 28 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas revenues $340.2 $342.6 $397.4 $350.4 $371.3 Y/Y 0% 2% 8% - 2% 9% Y/Y – CC - 1% 2% 8% - 2% 10% EMEA revenues $253.8 $229.7 $266.3 $251.0 $261.5 Y/Y 37% 35% 21% 30% 3% Y/Y – CC 23% 28% 22% 33% 10% AP

Slide 29: Total Oncology Systems revenues by sales classification
Total Oncology Systems revenues by sales classification 29 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $363.7 $326.9 $402.1 $366.6 $402.6 Y/Y 9% 29% 15% 8% 11% Y/Y – CC 7% 26% 15% 9% 14% Service revenues $334.3 $340.3 $353.5 $335.9 $344.2 Y/Y 13% 10% 11% 8% 3%

Slide 30: Total Oncology Systems revenues by region
Total Oncology Systems revenues by region 30 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas revenues $321.2 $323.2 $369.5 $330.8 $357.1 Y/Y - 3% 13% 6% - 2% 11% Y/Y – CC - 3% 13% 7% - 2% 12% EMEA revenues $241.2 $208.5 $250.0 $234.5 $245.3 Y/Y 44% 32% 27% 28% 2% Y/Y – CC

Slide 31: Total Proton Solutions revenues by sales classification
Total Proton Solutions revenues by sales classification 31 $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $30.1 $38.1 $43.4 $33.6 $27.9 Y/Y 0% - 43% - 12% 23% - 7% Service revenues $1.8 $3.8 $2.6 $4.9 $4.7 Y/Y 61% 95% - 23% 172% 151% Total revenues $31.9 $41.9 $46.0 $38.5 $32.6 Y/Y 2% -

Slide 32: Oncology Systems gross orders by region
Oncology Systems gross orders by region 32 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas orders $341.4 $362.9 $505.7 $335.9 $366.1 Y/Y 2% 9% 6% 12% 7% Y/Y – CC 2% 9% 6% 12% 8% EMEA orders $199.3 $259.1 $360.8 $218.3 $233.3 Y/Y 11% 27% 14% 15% 17% Y/Y – CC 0% 21% 15% 17%

Slide 33: Our promise: People powering victories
Our promise 33 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer
Source: SEC EDGAR · 8-K filed Apr 24, 2019
More decks from Varian Medical Systems Inc
Q1 FY2021 Earnings Presentation29 slides · Jan 26, 2021
Q4 FY2020 Earnings Presentation30 slides · Oct 27, 2020
Merger or Acquisition (August 2020)33 slides · Aug 4, 2020
Merger or Acquisition (August 2020)18 slides · Aug 3, 2020
Q3 FY2020 Earnings Presentation36 slides · Aug 3, 2020
Q2 FY2020 Earnings Presentation36 slides · May 4, 2020